Personalized or Standard Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: The PARTHENOPE Randomized Trial
Authors' conclusion
In patients undergoing PCI, a personalized DAPT duration from 3 to 24 months based on a clinical risk score led to a lowered risk of NACE than standard care consisting of 12 months of DAPT.
Study context
- Population
- Patients undergoing percutaneous coronary intervention (PCI)
- Participants
- 2,107 patients
- Comparison
- Personalized dual antiplatelet therapy (DAPT) duration vs standard 12-month DAPT
- Personalized DAPTn = 1,055
- Standard DAPTn = 1,052reference
- Primary endpoint
- Net adverse clinical event (NACE): all-cause death, MI, stroke, urgent target vessel revascularization, or BARC type 2, 3 or 5 bleeding
- Follow-up
- 24 months
Primary result
NACE
Difference
3.54 percentage points
95% CI −6.99 to −0.99
P = 0.040
Events by treatment group
As reported in the abstract
Further findings
| Outcome | Difference (percentage points) (95% CI) | |
|---|---|---|
| MI | −2.29 (−4.43 to −0.14) | |
| Urgent target vessel revascularization | −1.30 (−2.55 to −0.05) | |
| −6−4−202Difference, percentage points (linear scale) |
Safety
Bleeding (BARC type 2, 3 or 5) · 24 months
- Bleeding occurred at similar rates between the 2 groups
- difference −0.41 percentage points; 95% CI −2.92 to 2.10
Original publication
Personalized or Standard Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: The PARTHENOPE Randomized Trial. J Am Coll Cardiol. Published 30 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →